Proportion of patients without CCgR and the risk of progression after different time points
| Months after imatinib start . | No CCgR achieved* . | Patients who will later achieve CCgR (%)† . | Risk of progression after this time point† . |
|---|---|---|---|
| 3 | 93% (1168/1261) | 89% (1038/1168) | 7% (78/1168) |
| 6 | 69% (865/1261) | 85% (735/865) | 8% (66/865) |
| 9 | 35% (446/1261) | 71% (316/446) | 11% (50/446) |
| 12 | 26% (326/1261) | 60% (196/326) | 14% (47/326) |
| 15 | 18% (224/1261) | 42% (94/224) | 19% (43/224) |
| 18 | 15% (190/1261) | 31% (60/190) | 23% (43/190) |
| Months after imatinib start . | No CCgR achieved* . | Patients who will later achieve CCgR (%)† . | Risk of progression after this time point† . |
|---|---|---|---|
| 3 | 93% (1168/1261) | 89% (1038/1168) | 7% (78/1168) |
| 6 | 69% (865/1261) | 85% (735/865) | 8% (66/865) |
| 9 | 35% (446/1261) | 71% (316/446) | 11% (50/446) |
| 12 | 26% (326/1261) | 60% (196/326) | 14% (47/326) |
| 15 | 18% (224/1261) | 42% (94/224) | 19% (43/224) |
| 18 | 15% (190/1261) | 31% (60/190) | 23% (43/190) |